Should you buy Eli Lilly and stock now?
Yes, the technical signal for Eli Lilly and is currently BUY. Eli Lilly and trades at $1,179.30 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is negative (bearish trend) at -0.356 with falling momentum (signal: 7.730); RSI is at 51.3 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $1,276.96 points to 8.3% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Eli Lilly and stock?
The average analyst price target for Eli Lilly and is $1,276.96. The current price is $1,179.30, which gives an upside of 8.3%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $1,149.26 and $1,404.66.
Is Eli Lilly and a dividend stock?
Yes, Eli Lilly and is a dividend stock with a dividend yield of 0.56%. The latest dividend was $1.73 per share. The latest ex-dividend date (traded without the dividend) was 8/14/2026. The payout ratio is 29.0%, which is considered sustainable. The next dividend payment is scheduled for 9/10/2026.
When does Eli Lilly and pay a dividend in 2026?
Eli Lilly and pays its next dividend on 9/10/2026. The latest dividend was $1.73 per share with an ex-dividend date of 8/14/2026. The dividend yield is 0.56%. The payout ratio of 29.0% points to a sustainable dividend with room to grow.
What is the risk of Eli Lilly and stock?
Eli Lilly and is rated as a stock with moderate risk. the annual standard deviation is 38.5%, which classifies the stock as moderate risk.
Is Eli Lilly and overvalued?
Eli Lilly and is considered fairly valued – the price is close to the analyst price target. Eli Lilly and has the following valuation ratios: a P/E ratio of 39.6 (highly valued), a P/S ratio of 13.8, a P/B ratio of 32.8. The stock trades close to the analyst price target and is considered fairly valued.
Is Eli Lilly and overbought?
No, Eli Lilly and is not overbought. RSI is at 51.3 (neutral zone). The technical indicators show: RSI is at 51.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.6% above the 20-day average (short-term uptrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Eli Lilly and earnings report?
The date of the next earnings report for Eli Lilly and has not been published yet. Check the company's investor calendar for updates.
Is Eli Lilly and shorted?
Yes, Eli Lilly and is shorted with 1.2% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Eli Lilly and stock?
No, insiders are not buying Eli Lilly and shares – they are net sellers. Over the last 3 months, insiders have made 12 purchases and 2 sales. On a net basis, 3,880,651 $ worth of shares were sold. Across the last 20 reported transactions, the split is 17 purchases and 3 sales, with a net 17,402,282 $ sold. Active sellers include Seymour Melissa, Yuffa Ilya, LILLY ENDOWMENT INC. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Eli Lilly and a good stock?
Based on our total score, Eli Lilly and is rated as a good stock with a total score of 64 out of 100. The stock scores above average on value, quality and momentum – it is among the top 36% in our database. The score is made up of Value: 16/100, Quality: 97/100, Momentum: 79/100. In addition: a dividend of 0.56%; technical signal: Buy. Whether Eli Lilly and is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Eli Lilly and stock?
The outlook for Eli Lilly and based on current data: the average analyst price target is $1,276.96 (+8.3%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 39.6 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Eli Lilly and stock moving?
Eli Lilly and is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Eli Lilly and go?
The average analyst price target for Eli Lilly and is $1,276.96, which corresponds to a potential gain of 8.3% from the current price of $1,179.30. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Eli Lilly and fall?
We lack enough history to give a specific floor for Eli Lilly and. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Eli Lilly and do?
Eli Lilly and Company laver og sælger medicin til hele verden. De tjener hovedsageligt penge på at udvikle nye behandlinger, især inden for diabetes og kræft.
Eli Lilly er kendt for deres diabetesmidler som Humalog og Trulicity, men de sælger også vigtig kræftmedicin. For eks... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Eli Lilly and as an investment.
Did Eli Lilly and raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Eli Lilly and. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Eli Lilly and making money or losing money?
Yes, Eli Lilly and is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 35.0% — which is excellent. The operating margin (profit before interest and taxes) is 49.4%. At a P/E ratio of 39.6, you currently pay 39.6 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Eli Lilly and go bankrupt?
The bankruptcy risk of Eli Lilly and is rated as low. Altman Z2 (a model for assessing financial distress) is 3.34 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 9 — which is strong. Debt relative to equity is 454% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Eli Lilly and have a lot of debt?
Yes, Eli Lilly and has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 454%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
